Overview of the interplay between m6A methylation modification and non-coding RNA and their impact on tumor cells DOI Open Access

正則 兜,

Xiao-Ting Ma,

Mei-Na Piao

et al.

Translational Cancer Research, Journal Year: 2024, Volume and Issue: 13(6), P. 3106 - 3125

Published: June 1, 2024

: N6-methyladenosine (m6A) is one of the most common internal modifications in eukaryotic RNA. The presence m6A on transcripts can affect a series fundamental cellular processes, including mRNA splicing, nuclear transportation, stability, and translation. modification introduced by methyltransferases (writers), removed demethylases (erasers), recognized m6A-binding proteins (readers). Current research has demonstrated that methylation involved regulation malignant phenotypes tumors controlling expression cancer-related genes. Non-coding RNAs (ncRNAs) are diverse group RNA molecules do not encode widely present human genome. This includes microRNAs (miRNAs), long non-coding (lncRNAs), circular (circRNAs), PIWI interaction (piRNAs). They function as oncogenes or tumor suppressors through various mechanisms, regulating initiation progression cancer. Previous studies primarily focused coding RNAs, but recent discoveries have revealed significant regulatory role ncRNAs. Simultaneously, ncRNAs also exert their influence modulating translation, other biological processes m6A-related enzymes. interplay between collectively contributes to occurrence humans. review provides an overview interactions factors impact tumors.

Language: Английский

Long non-coding RNAs in lung cancer: Unraveling the molecular modulators of MAPK signaling DOI
Md Sadique Hussain, Obaid Afzal, Gaurav Gupta

et al.

Pathology - Research and Practice, Journal Year: 2023, Volume and Issue: 249, P. 154738 - 154738

Published: Aug. 6, 2023

Language: Английский

Citations

67
Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease DOI
Andrea Caporali, Maryam Anwar, Yvan Devaux

et al.

Nature Reviews Cardiology, Journal Year: 2024, Volume and Issue: 21(8), P. 556 - 573

Published: March 18, 2024

Language: Английский

Citations

20
Nanotherapeutic approaches for delivery of long non-coding RNAs: an updated review with emphasis on cancer DOI
Fatemeh Davodabadi, Shekoufeh Mirinejad, Sumira Malik

et al.

Nanoscale, Journal Year: 2024, Volume and Issue: 16(8), P. 3881 - 3914

Published: Jan. 1, 2024

The long noncoding RNAs (lncRNAs) comprise a wide range of RNA species whose length exceeds 200 nucleotides, which regulate the expression genes and cellular functions in organisms.

Language: Английский

Citations

11
Connecting the Dots: LncRNAs in the KRAS Pathway and Cancer DOI
Mudasir Maqbool, Md Sadique Hussain, Ajay Singh Bisht

et al.

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 262, P. 155570 - 155570

Published: Aug. 29, 2024

Language: Английский

Citations

10
M6A-modified lncRNA FAM83H-AS1 promotes colorectal cancer progression through PTBP1 DOI Creative Commons
Xiaojing Luo,

Yun‐Xin Lu,

Yun Wang

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 598, P. 217085 - 217085

Published: July 2, 2024

LncRNA plays a crucial role in cancer progression and targeting, but it has been difficult to identify the critical lncRNAs involved colorectal (CRC) progression. We identified FAM83H-AS1 as tumor-promoting associated lncRNA using 21 pairs of stage IV CRC tissues adjacent normal tissues. In vitro vivo experiments revealed that knockdown cells inhibited tumor proliferation metastasis, vice versa. M6A modification is for RNA stability through writer METTL3 readers IGF2BP2/IGFBP3. PTBP1-an binding protein-is responsible function CRC. T4 (1770-2440 nt) T5 (2440-2743 on exon 4 provide platform PTBP1 RRM2 interactions. Our results demonstrated m6A dysregulated oncogenic by phosphorylated its splicing effect. patient-derived xenograft models, ASO-FAM83H-AS1 significantly suppressed growth gastrointestinal (GI) tumors, not only also GC ESCC. The combination oxaliplatin/cisplatin compared with treatment either agent alone. Notably, there was pathological complete response all these three GI cancers. findings suggest targeted therapy would benefit patients primarily receiving platinum-based

Language: Английский

Citations

9
Long non-coding RNAs: Emerging regulators of invasion and metastasis in pancreatic cancer DOI Creative Commons
Mengmeng Shi, Rui Zhang, Hui Lyu

et al.

Journal of Advanced Research, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

The invasion and metastasis of pancreatic cancer (PC) are key factors contributing to disease progression poor prognosis. This process is primarily driven by EMT, which has been the focus recent studies highlighting role long non-coding RNAs (lncRNAs) as crucial regulators EMT. However, mechanisms lncRNAs influence invasive multifaceted, extending beyond EMT regulation alone. review aims characterize affecting in cancer. We summarize regulatory roles across multiple molecular pathways highlight their translational potential, considering implications for clinical applications diagnostics therapeutics. focuses on three principal scientific themes. First, we orchestrate various signaling pathways, such TGF-β/Smad, Wnt/β-catenin, Notch, regulate changes associated with thereby enhancing cellular motility invasivenes. Second, effects autophagy ferroptosis discuss exosomal tumor microenvironment behavior neighboring cells promote cell invasion. Third, emphasize RNA modifications (such m6A m5C methylation) stabilizing capacity mediate PC. Lastly, potential these findings, emphasizing inherent challenges using biomarkers therapeutic targets, while proposing prospective research strategies.

Language: Английский

Citations

1
Detection, molecular function and mechanisms of m5C in cancer DOI Creative Commons
Linhui Zhang, Yuelong Li, Liqing Li

et al.

Clinical and Translational Medicine, Journal Year: 2025, Volume and Issue: 15(3)

Published: Feb. 26, 2025

Language: Английский

Citations

1
RNA epigenetics in pulmonary diseases: Insights into methylation modification of lncRNAs in lung cancer DOI Open Access

Junjie Jiang,

Minghao Duan,

Zheng Wang

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 175, P. 116704 - 116704

Published: May 14, 2024

Long non-coding RNAs (lncRNAs) are pivotal controllers of gene expression through epigenetic mechanisms, Methylation, a prominent area study in epigenetics, significantly impacts cellular processes. Various RNA base methylations, including m6A, m5C, m1A, and 2'-O-methylation, profoundly influence lncRNA folding, interactions, stability, thereby shaping their functionality. LncRNAs methylation contribute to tumor development, especially lung cancer. Their roles encompass cell differentiation, proliferation, the generation cancer stem cells, modulation immune responses. Recent studies have suggested that dysregulation can development. Furthermore, modifications lncRNAs hold potential for clinical application Dysregulated promote progression may offer insights into biomarker or therapeutic target. This review summarizes current knowledge its implications epigenetics pulmonary diseases.

Language: Английский

Citations

6
Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy DOI Creative Commons
Rajkumar Prabhakaran,

Rajkumar Thamarai,

Sivabalan Sivasamy

et al.

Epigenetics & Chromatin, Journal Year: 2024, Volume and Issue: 17(1)

Published: Oct. 16, 2024

Cancer has arisen from both genetic mutations and epigenetic changes, making epigenetics a crucial area of research for innovative cancer prevention treatment strategies. This dual perspective propelled into the forefront research. review highlights important roles DNA methylation, histone modifications non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) long RNAs, which are key regulators cancer-related gene expression. It explores potential epigenetic-based therapies to revolutionize patient outcomes by selectively modulating specific markers involved in tumorigenesis. The examines promising biomarkers early detection prognosis. also recent progress oligonucleotide-based therapies, including antisense oligonucleotides (ASOs) antimiRs, precisely modulate processes. Furthermore, concept editing is discussed, providing insight future role precision medicine patients. integration nanomedicine therapy been explored offers approaches improve therapeutic efficacy. comprehensive advances seeks advance field oncology, ultimately culminating improved fight against cancer.

Language: Английский

Citations

6
The Emerging, Multifaceted Role of WTAP in Cancer and Cancer Therapeutics DOI Open Access

Guomin Ju,

Jiangchu Lei,

Shuqi Cai

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(11), P. 3053 - 3053

Published: June 4, 2023

Cancer is a grave and persistent illness, with the rates of both its occurrence death toll increasing at an alarming pace. N6-methyladenosine (m6A), most prevalent mRNA modification in eukaryotic organisms, catalyzed by methyltransferases has significant impact on various aspects cancer progression. WT1-associated protein (WTAP) crucial component m6A methyltransferase complex, catalyzing methylation RNA. It been demonstrated to participate numerous cellular pathophysiological processes, including X chromosome inactivation, cell proliferation, cycle regulation, alternative splicing. A better understanding role WTAP may render it reliable factor for early diagnosis prognosis, as well key therapeutic target treatment. found that closely related tumor metabolic autophagy, immunity, ferroptosis, epithelial mesenchymal transformation (EMT), drug resistance. In this review, we will focus latest advances biological functions cancer, explore prospects application clinical therapy.

Language: Английский

Citations

13